sk&f 104976 has been researched along with 5,22-cholestadien-3beta-ol in 1 studies
Studies (sk&f 104976) | Trials (sk&f 104976) | Recent Studies (post-2010) (sk&f 104976) | Studies (5,22-cholestadien-3beta-ol) | Trials (5,22-cholestadien-3beta-ol) | Recent Studies (post-2010) (5,22-cholestadien-3beta-ol) |
---|---|---|---|---|---|
10 | 0 | 1 | 8 | 0 | 1 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Busto, R; Cano, S; Dávalos, A; de la Peña, G; Giera, M; Herrera, E; Lasunción, MA; Sánchez-Wandelmer, J | 1 |
1 other study(ies) available for sk&f 104976 and 5,22-cholestadien-3beta-ol
Article | Year |
---|---|
Inhibition of cholesterol biosynthesis disrupts lipid raft/caveolae and affects insulin receptor activation in 3T3-L1 preadipocytes.
Topics: 3T3-L1 Cells; Animals; Caveolae; Caveolin 1; Cell Membrane; Cholesterol; Dehydrocholesterols; Enzyme Inhibitors; G(M1) Ganglioside; Lanosterol; Membrane Microdomains; Mice; Receptor, Insulin; trans-1,4-Bis(2-chlorobenzaminomethyl)cyclohexane Dihydrochloride; Triparanol | 2009 |